Oxford Biomedica Licenses Viral Vector Platforms to Australian CDMO VVMF

Oxford Biomedica (LSE:OXB) has entered a five-year licensing and option agreement with Viral Vector Manufacturing Facility (VVMF), Australia’s first dedicated commercial viral vector contract development and manufacturing organisation. The deal grants VVMF a worldwide, non-exclusive licence to Oxford Biomedica’s inAAVate platform, along with an option to access its LentiVector technology.

Under the terms of the agreement, Oxford Biomedica will receive an upfront payment in the low single-digit millions, with the potential for additional payments in the future. VVMF intends to use the licensed technologies to accelerate the development of its viral vector manufacturing capabilities and support the build-out of advanced production infrastructure.

The collaboration is expected to strengthen Australia’s position as a hub for cell and gene therapy manufacturing within the Asia-Pacific region while expanding Oxford Biomedica’s global presence. The agreement also reinforces the company’s role as a provider of scalable viral vector technologies used by pharmaceutical and biotechnology partners worldwide.

Despite strong recent revenue growth, Oxford Biomedica’s broader outlook remains constrained by financial challenges, including continued losses, negative cash flow and relatively high leverage. Market technical indicators currently appear supportive, with the shares trading in a clear uptrend and showing positive MACD momentum. However, very elevated RSI and stochastic readings suggest the stock may be overbought in the near term. Valuation metrics also remain limited due to negative earnings and the absence of a dividend yield.

More about Oxford Biomedica

Oxford Biomedica is a UK-headquartered contract development and manufacturing organisation specialising in cell and gene therapy. With roughly three decades of experience in viral vector technology, the company provides end-to-end development and manufacturing services for lentiviral, adeno-associated and other viral vectors. Its clients include global pharmaceutical and biotechnology companies, supported by proprietary platform technologies and manufacturing facilities located in the UK, France and the United States.